NOTICE TO CONVENE ANNUAL GENERAL MEETING 2024
GUBRA A/S CVR NO. 30 51 40 41 To the shareholders of Gubra A/S (CVR no. 30 51 40 41), notice is hereby given of the annual general meeting of Gubra A/S (the "Company") to be held on: THURSDAY, 4…
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S’ shares
Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in the Company and persons closely associated with them in…
Annual Report 2023 – Revenue in the CRO business growing by 29% to record high level
In 2023, organic revenue growth in the CRO business was 29% compared to latest guidance of 25-28%, while adjusted EBIT-margin amounted to 27.4% (guidance 26-28%). Revenue in the Discovery & Partnerships business (D&P) amounted to DKK 36.5 million compared to…
Annual Report 2023: CEO video statement
In 2023, we increased our revenue by 29% in our CRO service business. This is a company record. In Discovery & Partnerships, we also made significant advances last year. We signed two new partnerships with Hemab and Boehringer Ingelheim. We…
Gubra concludes the research agreement with UK Biotech
Today, Gubra announces the finalization of its two-year explorative research agreement with Silence Therapeutics PLC that was signed in early 2022. The collaboration concerned early target discovery of RNAi therapies for liver diseases. In collaboration with Silence Therapeutics, we have…
Gubra and Boehringer Ingelheim sign 4th partnership, expanding their successful obesity treatment discovery collaboration
Today, Gubra announces the signing of a new research and license agreement with Boehringer Ingelheim to discover novel peptides for the treatment of obesity. The new research collaboration builds on the successfully progressing joint research projects between the companies. It…
GAN DIO-MASH model is top-ranked by the LITMUS consortium
Gubra’s GAN DIO-MASH mouse model has been top-ranked by the LITMUS¹ consortium for its human proximity score. The LITMUS consortium has evaluated a wide variety of preclinical MASH models using two key parameters, metabolic significance and ability to induce fibrosis. In…
Gubra announces first subject dosed in Phase 1 clinical trial of amylin agonist (GUBamy) for the treatment of obesity
Today, Gubra announces that the first human subject has been dosed with a new long-acting amylin agonist (GUBamy) as a potential treatment for obesity. This first clinical trial is a single ascending, dose-escalation, safety, and tolerability trial in healthy volunteers…
Trading statement Q3-2023: Continued strong performance
Today, Gubra released its trading statement for the third quarter of 2023. Organic revenue grew by 44% year-over-year in Q3-2023 (9M: 28%) for the CRO business with an adjusted EBIT-margin of 31% (9M: 28%). FY-2023 outlook for organic revenue growth…
Trading statement Q3-2023: CEO video statement
Today we publish our Q3 trading statement focusing closely on the performance of the company during the third quarter of 2023. Watch this video with CEO of Gubra Henrik Blou where he covers most of it in 3 minutes. Contacts…